ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,011.12
-0.22%
US Tech 100
16,906.80
-0.74%
Dow Jones
37,775.38
0.06%
Brent Oil
86.415
-0.66%
Bitcoin
63,503.41
3.62%
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Krystal Biotech Inc (KRYS) Quote

Krystal Biotech Inc

Krystal Biotech Inc (KRYS)

NASDAQ
163.97
-5.67
(-3.34%)
At close: April 18 4:00PM
Delayed by 15 minutes
163.97
-5.67
( -3.34% )
After Hours: 5:30PM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
163.97
Bid
163.00
Ask
199.19
Volume
281,100
163.45 Day's Range 171.455
82.09 52 Week Range 189.97
Market Cap
4.645B
Previous Close
169.64
Open
167.97
Last Trade
5956
@
163.97
(formt)
Last Trade Time
17:04:19
Financial Volume
$ 47,081,149
VWAP
167.489
Average Volume (3m)
407,748
Shares Outstanding
28,292,616
Dividend Yield
-
PE Ratio
424.92
Earnings Per Share (EPS)
0.39
Revenue
50.7M
Net Profit
10.93M

About Krystal Biotech Inc

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments... Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.krystalbio.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Krystal Biotech Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker KRYS. The last closing price for Krystal Biotech was $169.64. Over the last year, Krystal Biotech shares have traded in a share price range of $ 82.09 to $ 189.97.

Krystal Biotech currently has 28,292,616 shares outstanding. The market capitalization of Krystal Biotech is $4.65 billion. Krystal Biotech has a price to earnings ratio (PE ratio) of 424.92.

Krystal Biotech (KRYS) Options Flow Summary

KRYS Options Flow

Overall Flow

Bullish

Net Premium

3M

Calls / Puts

150.00%

Buys / Sells

66.67%

OTM / ITM

150.00%

Sweeps Ratio

0.00%

KRYS Latest News

More News

Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting

PITTSBURGH, April 04, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting...

April 04 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

March 01 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

March 01 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

February 28 2024
Edgar (US Regulatory)

Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference

PITTSBURGH, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in...

February 28 2024
GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities

February 26 2024
Edgar (US Regulatory)

Form 8-K - Current report

February 26 2024
Edgar (US Regulatory)

Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

•  Net product revenue of $42.1M in 4Q and $50.7M for the year •  New England Journal of Medicine publication of the use of B-VEC eyedrop formulation •  Reached alignment with FDA to enable...

February 26 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-12.66-7.16752533545176.63180.57163.45219412172.55514337CS
4-8.37-4.85667865847172.34182.51163.45262469175.2891423CS
1234.4226.5688923196129.55189.97107.5407748153.07301165CS
2649.6343.4056323246114.34189.9793.95357222134.15372961CS
5275.0284.339516582388.95189.9782.09320763125.72905764CS
15687.5114.42395710776.47189.9738.856324125994.40865569CS
260133.57439.37530.4189.9722.0220971080.51032562CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ZCMDZhongchao Inc
$ 2.40
(65.52%)
2.77M
WLGSWang and Lee Group Inc
$ 0.74
(48.00%)
1.77M
PEVPhoenix Motor Inc
$ 0.8288
(18.60%)
40.53k
GDHGGolden Heaven Group Holdings Ltd
$ 0.3097
(17.76%)
10.39M
TCTuanChe Ltd
$ 2.1899
(17.11%)
207.85k
GGEGreen Giant Inc
$ 0.0247
(-31.77%)
40.63M
BGLCBioNexus Gene Lab Corporation
$ 0.65
(-23.40%)
452.17k
VALNValneva SE
$ 7.10
(-12.67%)
100
TIRXTian Ruixiang Holdings Ltd
$ 0.71
(-11.25%)
534.61k
ISPCiSpecimen Inc
$ 0.378
(-10.21%)
715.15k
GGEGreen Giant Inc
$ 0.0247
(-31.77%)
40.63M
SINTSiNtx Technologies Inc
$ 0.0394
(-1.50%)
13.01M
GDHGGolden Heaven Group Holdings Ltd
$ 0.31
(17.87%)
10.41M
GRABGrab Holdings Ltd
$ 3.41
(0.59%)
4.33M
EGOXNext e GO NV
$ 0.0377
(4.72%)
3.51M

KRYS Discussion

View Posts
Monksdream Monksdream 2 weeks ago
KRYS over $30
👍️0
Monksdream Monksdream 1 month ago
KRYS new 52 week high
👍️0
Monksdream Monksdream 10 months ago
From Cathie Wood
A Novel Gene Therapy Promises Relief For A Rare Genetic Skin Disorder
ARK Invest_Illustration_Pierce Jamieson_Final_Circle 400 px By Pierce Jamieson | @PierceARK
Research Associate
Recently, the US Food and Drug Administration (FDA) approved Krysta Biotech’s (KRYS) groundbreaking advance1 in gene therapy, Vyjuvek, to treat wounds in patients suffering from dystrophic epidermolysis bullosa (DEB), a rare and serious genetic skin disorder caused by mutations in the collagen Type VII alpha 1 chain (COL7A1) gene. As the first FDA-approved gene therapy for DEB, Vyjuvek is a significant breakthrough.

Vyjuvek uses a genetically modified HSV-1 to deliver normal copies of the COL7A1 gene to wounds, restoring the integrity of the skin with fibrils that hold skin layers together. Treated with Vyjuvek, 65% of wounds closed completely.
👍️0
wiredawg wiredawg 2 years ago
Moving nicely today...
👍️0
wiredawg wiredawg 2 years ago
Looking at the few posts here there seems to be no real commitment here...any thoughts on KRYS? Hype or something brewing?
👍️0
wiredawg wiredawg 2 years ago
In the last 3 months, 5 ranked analysts set 12-month price targets for KRYS. The average price target among the analysts is $125.00. Analysts compare their price target to the current market price of the stock to determine how much potential upside or downside movement there could be in the stock price. High $140 Low $111

👍️0
wiredawg wiredawg 2 years ago
30 Nov Tues releases this PR during evening after market close:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-pricing-200-million-public-offering
👍️0
wiredawg wiredawg 2 years ago
29 Nov Mon after market closes release this PR:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-proposed-200-million-public-offering
👍️0
wiredawg wiredawg 2 years ago
29 Nov Monday pre-market news release, great move pre-market approx 7am and so far holding fairly well:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-positive-topline-results-gem-3-pivotal
👍️0
wiredawg wiredawg 2 years ago
This caught my eye on Monday, the huge move off the PR...I'm guessing here saw the same. Any real thoughts regarding the company and this PR. I have not gotten a chance to dig into it. Hoping to have somm DD done over the weekend.
👍️0
wiredawg wiredawg 2 years ago
Holding well so far, why the pretty hard drop?
👍️0
wiredawg wiredawg 2 years ago
Why are you surprised? Serious question, not being impudent...
👍️0
rynlrt rynlrt 2 years ago
200 million dollar offering. Won't be surprised to see it drop pretty hard when the market opens
👍️0
Fofo812 Fofo812 2 years ago
Surprised it held up this long
👍️0
crudeoil24 crudeoil24 2 years ago
Large tutes holdings. Some taking huge gains before years end.
👍️0
rynlrt rynlrt 2 years ago
Not sure this kind of gain is sustainable. May see a big pullback
👍️0
Fofo812 Fofo812 2 years ago
3rd post
👍️0
crudeoil24 crudeoil24 2 years ago
Krystal Biotech shares are trading higher after the company announced its GEM-3 trial met its primary endpoint.
👍️0
Trophy Trophy 4 years ago
..
👍️0

Your Recent History

NASDAQ
KRYS
Krystal Biotech
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved